Biomarker for abdominal aortic aneurysm

Patent metadata

Field	Value
Publication number	US-10047386-B2
Application number	US-201214349828-A
Country	US
Kind code	B2
Filing date	Oct 11, 2012
Priority date	Oct 11, 2011
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and/or for treatment for AAA.

First claim

What is claimed is:

1. A method for treating abdominal aortic aneurysm (AAA) in a subject, the method comprising:
(a) contacting a test sample consisting of serum, plasma or whole blood from a subject with an assay device capable of measuring the amount of tetrahydrobiopterin (H 4 B) present in the test sample, wherein the test sample is serum, plasma or whole blood;
(b) measuring the amount of H 4 B present in the test sample, wherein the test sample has a decreased amount of H 4 B relative to a standard amount of H 4 B; and
(c) treating the subject for AAA with oral administration of folic acid.

2. The method of claim 1 , wherein the assay device comprises a high performance liquid chromatography (HPLC) column.

3. The method of claim 1 , wherein the assay device comprises an immunoassay kit.

4. The method of claim 1 , wherein the decreased amount is a 20% decrease in the amount of H 4 B present in the test sample compared to the standard.

5. The method of claim 1 , wherein the decreased amount is a 50% decrease in the amount of H 4 B present in the test sample compared to the standard.

6. The method of claim 1 , wherein the sample is plasma.

7. The method of claim 1 , further comprising:
(c) contacting a second test sample from the subject obtained at a second time point with an assay device capable of measuring the amount of tetrahydrobiopterin (H 4 B) present in the test sample;
(d) measuring the amount of tetrahydrobiopterin (H 4 B) present in the second test sample;
wherein treatment with folic acid therapy is administered to the subject prior to the second time point.

8. The method of claim 7 , wherein a 20% increase is measured in the amount of H 4 B present in the second test sample compared to the measured amount of step (b).

9. The method of claim 7 , further comprising prescribing a modified treatment for AAA to the subject whose H 4 B is decreased in the second test sample compared to the measured amount of step (b).

10. The method of claim 9 , wherein the H 4 B in the second test sample is decreased 50% compared to the standard.

11. A method for treating abdominal aortic aneurysm (AAA) in a subject, the method comprising:
(a) measuring, in a test sample of serum, plasma or whole blood from the subject, the amount of tetrahydrobiopterin (H 4 B) present in the test sample; wherein a 20% decrease is detected in the measured amount of H 4 B present in the test sample relative to a standard amount of H 4 B; and
(b) treating the subject with oral administration of folic acid.

12. The method of claim 1 , wherein the decreased amount is a 30% decrease in the amount of H 4 B present in the test sample compared to the standard.

13. The method of claim 1 , wherein the decreased amount is a 40% decrease in the amount of H 4 B present in the test sample compared to the standard.

14. The method of claim 11 , wherein the decrease is a 30% decrease in the amount of H 4 B present in the test sample compared to the standard.

15. The method of claim 11 , wherein the decrease is a 40% decrease in the amount of H 4 B present in the test sample compared to the standard.

16. The method of claim 11 , wherein the decrease is a 50% decrease in the amount of H 4 B present in the test sample compared to the standard.

17. The method of claim 7 , wherein a 30% increase is measured in the amount of H 4 B present in the second test sample compared to the measured amount of step (b).

18. The method of claim 7 , wherein a 40% increase is measured in the amount of H 4 B present in the second test sample compared to the measured amount of step (b).

Assignees

• Univ California

Inventors

• Cai Hua

Classifications

• Y10T436/147777

  Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.] · CPC title

• G01N2800/329

  Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection · CPC title

• C12Q1/37

  involving peptidase or proteinase · CPC title

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title